Pharmacotherapy in Diabetic Neuropathy
Diabetic neuropathy was defined at the San Antonio Consensus Conference as “a descriptive term meaning a demonstrable nerve disorder, either clinically evident or subclinical, that occurs in the setting of diabetes mellitus without other causes for peripheral neuropathy. The neuropathic disorder includes manifestations in the somatic or autonomic parts of the peripheral nervous system” . Diabetic neuropathy is a chronic condition caused by hyperglycaemia, characterized by progressive morphological destruction of the peripheral nervous system, accompanied by loss of peripheral nerve function. Clinically, loss of function is defined by distal loss of sensibility, muscular strength and loss of deep tendon reflexes as well as by autonomic dysfunction of viscera and blood vessels.
KeywordsDiabetic Neuropathy Autonomic Neuropathy Nerve Conduction Velocity Diabetic Peripheral Neuropathy Painful Diabetic Neuropathy
Unable to display preview. Download preview PDF.
- 1.Consensus statement. Report and recommendation of the San Antonio Conference on diabetic neuropathy. American Diabetes Association American Academy of Neurology. Diabetes Care 1988;11:592–597.Google Scholar
- 2.Pirart J. Diabetes mellitus and its generative complications: A prospective study of 4400 patients observed. Diabetes Care 1978;1:168–188.Google Scholar
- 6.Sima AAF, Pierson CR. Pathogenesis and Pathology of diabetic neuropathy. In: Gries FA, editor. Textbook of diabetic neuropathy, Stuttgart. New York: Georg Thieme verlag, 2003, 83–169.Google Scholar
- 8.Dyck P. Pathology and pathophysiology- Human and experimental. In Dyck PJ, editor. Diabetic neuropathy. London: WB Saunders Company, 1987, 223–237.Google Scholar
- 16.Ekberg K, Brismar T, Johansson BL et al. Amelioration of sensory nerve dysfunction by C-peptide in patients with Type 1 Diabetes. 2003;52:536–541.Google Scholar
- 17.Obrosova IG, Pacher P, Szab C et al. Aldose reductase inhibition counteracts oxidative-nitrosative stress and poly(ADP-ribose) polymerase activation in tissue sites for diabetic complications. Diabetes Nutr Metab. 2005;54:234–242.Google Scholar
- 31.Morello CM, Leckband SG, Stoner CP et al. Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. ArchIntern Med 1999;159:1931–1937.Google Scholar
- 32.Griesing T, Freeman R Rosenstock et al. Efficacy, safety and tolerability og pregabalin treatment for diabetic peripheral neuropathy: findings from 6 randomized controlled trials. Diabetologia 2005;48 (suppl 1):A351.Google Scholar